KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Cash: 2010-2024

Historic Change in Cash for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to -$5.7 million.

  • Supernus Pharmaceuticals' Change in Cash rose 139.72% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 291.35%. This contributed to the annual value of -$5.7 million for FY2024, which is 68.32% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Change in Cash is -$5.7 million, which was up 68.32% from -$18.1 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Change in Cash high stood at $107.3 million for FY2020, and its period low was -$110.3 million during FY2022.
  • For the 3-year period, Supernus Pharmaceuticals' Change in Cash averaged around -$44.7 million, with its median value being -$18.1 million (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Change in Cash skyrocketed by 1,087.02% in 2020 and then plummeted by 179.44% in 2021.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Change in Cash stood at $107.3 million in 2020, then slumped by 179.44% to -$85.2 million in 2021, then fell by 29.47% to -$110.3 million in 2022, then skyrocketed by 83.62% to -$18.1 million in 2023, then spiked by 68.32% to -$5.7 million in 2024.